![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ADAM9 |
Gene summary for ADAM9 |
![]() |
Gene information | Species | Human | Gene symbol | ADAM9 | Gene ID | 8754 |
Gene name | ADAM metallopeptidase domain 9 | |
Gene Alias | CORD9 | |
Cytomap | 8p11.22 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q13443 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8754 | ADAM9 | CA_HPV_2 | Human | Cervix | CC | 2.03e-03 | 2.30e-01 | 0.0391 |
8754 | ADAM9 | CCI_2 | Human | Cervix | CC | 2.23e-05 | 7.61e-01 | 0.5249 |
8754 | ADAM9 | CCI_3 | Human | Cervix | CC | 7.38e-03 | 5.06e-01 | 0.516 |
8754 | ADAM9 | Tumor | Human | Cervix | CC | 3.07e-02 | 2.06e-01 | 0.1241 |
8754 | ADAM9 | sample3 | Human | Cervix | CC | 2.17e-10 | 3.19e-01 | 0.1387 |
8754 | ADAM9 | H2 | Human | Cervix | HSIL_HPV | 2.20e-03 | 1.97e-01 | 0.0632 |
8754 | ADAM9 | T3 | Human | Cervix | CC | 8.98e-07 | 3.24e-01 | 0.1389 |
8754 | ADAM9 | LZE4T | Human | Esophagus | ESCC | 1.13e-12 | 5.06e-01 | 0.0811 |
8754 | ADAM9 | LZE7T | Human | Esophagus | ESCC | 1.55e-04 | -1.60e-02 | 0.0667 |
8754 | ADAM9 | LZE8T | Human | Esophagus | ESCC | 4.43e-11 | 2.42e-01 | 0.067 |
8754 | ADAM9 | LZE20T | Human | Esophagus | ESCC | 9.56e-19 | 1.14e+00 | 0.0662 |
8754 | ADAM9 | LZE22D1 | Human | Esophagus | HGIN | 1.83e-04 | -4.57e-02 | 0.0595 |
8754 | ADAM9 | LZE22T | Human | Esophagus | ESCC | 1.88e-02 | 7.52e-01 | 0.068 |
8754 | ADAM9 | LZE24T | Human | Esophagus | ESCC | 8.35e-21 | 7.82e-01 | 0.0596 |
8754 | ADAM9 | LZE21T | Human | Esophagus | ESCC | 6.59e-05 | 1.64e-01 | 0.0655 |
8754 | ADAM9 | P1T-E | Human | Esophagus | ESCC | 4.14e-04 | 5.85e-01 | 0.0875 |
8754 | ADAM9 | P2T-E | Human | Esophagus | ESCC | 6.66e-24 | 3.20e-01 | 0.1177 |
8754 | ADAM9 | P4T-E | Human | Esophagus | ESCC | 2.16e-24 | 6.14e-01 | 0.1323 |
8754 | ADAM9 | P5T-E | Human | Esophagus | ESCC | 2.63e-15 | 1.99e-01 | 0.1327 |
8754 | ADAM9 | P8T-E | Human | Esophagus | ESCC | 1.17e-39 | 9.66e-01 | 0.0889 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004217610 | Cervix | CC | regulation of protein catabolic process | 104/2311 | 391/18723 | 9.39e-15 | 9.36e-12 | 104 |
GO:00315898 | Cervix | CC | cell-substrate adhesion | 96/2311 | 363/18723 | 1.48e-13 | 8.85e-11 | 96 |
GO:004586210 | Cervix | CC | positive regulation of proteolysis | 95/2311 | 372/18723 | 1.84e-12 | 6.86e-10 | 95 |
GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
GO:004573210 | Cervix | CC | positive regulation of protein catabolic process | 65/2311 | 231/18723 | 7.44e-11 | 1.39e-08 | 65 |
GO:00435884 | Cervix | CC | skin development | 71/2311 | 263/18723 | 8.04e-11 | 1.46e-08 | 71 |
GO:004578510 | Cervix | CC | positive regulation of cell adhesion | 101/2311 | 437/18723 | 1.96e-10 | 3.08e-08 | 101 |
GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
GO:001063210 | Cervix | CC | regulation of epithelial cell migration | 72/2311 | 292/18723 | 4.52e-09 | 4.43e-07 | 72 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:00071608 | Cervix | CC | cell-matrix adhesion | 60/2311 | 233/18723 | 1.58e-08 | 1.23e-06 | 60 |
GO:00302164 | Cervix | CC | keratinocyte differentiation | 42/2311 | 139/18723 | 1.74e-08 | 1.28e-06 | 42 |
GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
GO:00099137 | Cervix | CC | epidermal cell differentiation | 53/2311 | 202/18723 | 5.48e-08 | 3.25e-06 | 53 |
GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ADAM9 | SNV | Missense_Mutation | novel | c.53N>G | p.Leu18Arg | p.L18R | Q13443 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-VQ-A8PB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | CR |
ADAM9 | insertion | In_Frame_Ins | novel | c.2066_2067insGCTTAC | p.Asn689delinsLysLeuThr | p.N689delinsKLT | Q13443 | protein_coding | TCGA-EL-A3ZN-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8754 | ADAM9 | DRUGGABLE GENOME, PROTEASE, NEUTRAL ZINC METALLOPEPTIDASE, CELL SURFACE, ENZYME | inhibitor | 178103981 | ILOMASTAT |
Page: 1 |